Reported Earnings • Jul 01
Full year 2026 earnings released: EPS: CN¥0.07 (vs CN¥0.11 loss in FY 2025) Full year 2026 results: EPS: CN¥0.07 (up from CN¥0.11 loss in FY 2025). Revenue: CN¥819.3m (up 15% from FY 2025). Net income: CN¥72.7m (up CN¥190.5m from FY 2025). Profit margin: 8.9% (up from net loss in FY 2025). Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Duyuru • Jul 01
Yidu Tech Inc. announces Annual dividend, payable on September 16, 2026 Yidu Tech Inc. announced Annual dividend of HKD 0.0400 per share payable on September 16, 2026, ex-date on September 01, 2026 and record date on September 02, 2026. Duyuru • Jun 30
Yidu Tech Inc., Annual General Meeting, Aug 28, 2026 Yidu Tech Inc., Annual General Meeting, Aug 28, 2026. Duyuru • Jun 09
Yidu Tech Inc. to Report Fiscal Year 2026 Results on Jun 22, 2026 Yidu Tech Inc. announced that they will report fiscal year 2026 results on Jun 22, 2026 Board Change • May 21
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Linqi Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • Feb 14
Yidu Tech Inc. Announces Resignation of Executive Director Dr. Xie Li, Effective February 13, 2026 Yidu Tech Inc. announced that Dr. Xie Li has tendered her resignation as an executive Director with effect from February 13, 2026 as she plans to devote more time to her personal matters. Duyuru • Nov 17
Yidu Tech Inc. to Report First Half, 2026 Results on Nov 27, 2025 Yidu Tech Inc. announced that they will report first half, 2026 results on Nov 27, 2025 Duyuru • Jun 25
Yidu Tech Inc., Annual General Meeting, Aug 29, 2025 Yidu Tech Inc., Annual General Meeting, Aug 29, 2025. Duyuru • Jun 13
Yidu Tech Inc. to Report Fiscal Year 2025 Results on Jun 25, 2025 Yidu Tech Inc. announced that they will report fiscal year 2025 results on Jun 25, 2025 Duyuru • Jan 27
Yidu Tech Inc. Announces Board Changes Yidu Tech Inc. announced that Dr. Xie Li (Dr. Xie) has been appointed as an executive director with effect from 27 January 2025. Dr. Xie Li, MD, PhD, aged 48, has served as the Head of Innovative Medicine and Real-World Evidence Department at Tianjin Happy Life Technology Co. Ltd., since May 2022. Dr. Xie has nearly ten years of experience as a clinical doctor and more than ten years of working experience in the medical affairs, health economics, and outcomes research departments at top ten multinational pharmaceutical companies, and serves as a member of the Professional Committee on Pharmaceutical Policy and Evaluation of the National Association of Health Industry and Enterprise Management and an external expert at the China-Australia Joint Research Center for Infectious Diseases jointly established by Monash University in Australia and Xi'an Jiaotong University Health Science Centre. She has supported the launch of the most successful pharmaceutical products in China and several first-in-class drugs, as well as market access work including medical insurance negotiations, centralized procurement, and commercial insurance. Dr. Xie has extensive industry experience in the medical, pharmaceutical, and health insurance fields. Her major research areas focus on real-world studies and health economics research, collaboration with research institutes and pharmaceutical and medical device companies to promote the application of AI and big data in healthcare and health insurance. Dr. Xie was the awardee of the scientific and technological second prize of Shaanxi Province and the recipient of multiple research grants. She collaborated with research institutions including Shanghai Fudan University, Peking University, Capital Medical University, the Health Development Research Center of the National Health Commission and the Shanghai Health Development Research Center and jointly published the Research Report on the Value Evaluation and Practical Application of High-Value Medical Consumables which is the most complete evaluation system of high-value medical consumables with the most comprehensive value dimension in China, and has published over 20 papers in renowned academic journals and conferences, including the Journal of Hepatology, Hepatology, JAMA Network Open, and ISPOR. Dr. Xie obtained her Doctor of Medicine degree from Xi'an Jiaotong University in December 2019. The board of the company announced that Dr. Yan Jun (Dr. Yan) has tendered his resignation as an executive director the company, with effect from 27 January 2025, to focus on the company's technology research and development work. Dr. Yan has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the company. Dr. Yan will remain as the Chief Technology Officer of the Company and the Chief AI Scientist of the Group. Duyuru • Nov 11
Yidu Tech Inc. to Report First Half, 2025 Results on Nov 21, 2024 Yidu Tech Inc. announced that they will report first half, 2025 results on Nov 21, 2024 Buy Or Sell Opportunity • Oct 10
Now 32% undervalued Over the last 90 days, the stock has risen 1.5% to €0.40. The fair value is estimated to be €0.58, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Earnings per share has grown by 107%. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 63% per annum over the same time period. Reported Earnings • Jul 30
Full year 2024 earnings released: CN¥0.18 loss per share (vs CN¥0.63 loss in FY 2023) Full year 2024 results: CN¥0.18 loss per share (improved from CN¥0.63 loss in FY 2023). Revenue: CN¥807.1m (flat on FY 2023). Net loss: CN¥194.9m (loss narrowed 69% from FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Jul 02
Now 38% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.1% to €0.44. The fair value is estimated to be €0.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Earnings per share has grown by 107%. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 58% per annum over the same time period. New Risk • Jul 01
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CN¥195m Forecast net loss in 3 years: CN¥90m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CN¥90m net loss in 3 years). Share price has been volatile over the past 3 months (9.8% average weekly change). Breakeven Date Change • Jul 01
No longer forecast to breakeven The 4 analysts covering Yidu Tech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CN¥42.7m in 2026. New consensus forecast suggests the company will make a loss of CN¥90.0m in 2027. Reported Earnings • Jun 28
Full year 2024 earnings released: CN¥0.19 loss per share (vs CN¥0.63 loss in FY 2023) Full year 2024 results: CN¥0.19 loss per share (improved from CN¥0.63 loss in FY 2023). Revenue: CN¥807.1m (flat on FY 2023). Net loss: CN¥194.9m (loss narrowed 69% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Duyuru • Jun 28
Yidu Tech Inc., Annual General Meeting, Aug 30, 2024 Yidu Tech Inc., Annual General Meeting, Aug 30, 2024. Duyuru • Jun 19
Beijing Yier Technology Co., Ltd. Passes Deep Synthetic Service Algorithm Filing of the Cyberspace Administration of China Yidu Tech Inc. announced that both the Yidu Happy Health Large Model Algorithm and Yidu Happy Health Large Model Service Algorithm of Beijing Yier Technology Co. Ltd. have recently passed the deep synthesis service algorithm filing of the Cyberspace Administration of China. Leveraging the proprietary intelligent AI medical brain, YiduCore, that accumulated multi-dimensional, quantifiable knowledge graphs over a decade and integrated advanced large model technology, Yidu Tech applies medical intelligence solutions in three major categories of healthcare scenarios, namely research, diagnosis and treatment and public health, to help reduce the cost of healthcare services, enhance the efficiency of the healthcare industry's supply side, and to promote the establishment of an inclusive, precise, and efficient intelligent healthcare system. Buy Or Sell Opportunity • Jun 19
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 14% to €0.43. The fair value is estimated to be €0.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 43% over the last year. Earnings per share has grown by 50%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 65% per annum over the same time period. Duyuru • Jun 15
Yidu Tech Inc. to Report Fiscal Year 2024 Results on Jun 27, 2024 Yidu Tech Inc. announced that they will report fiscal year 2024 results on Jun 27, 2024 Buy Or Sell Opportunity • Jun 11
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.9% to €0.44. The fair value is estimated to be €0.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 43% over the last year. Earnings per share has grown by 50%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 65% per annum over the same time period. New Risk • Apr 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CN¥24m net loss in 3 years). Buy Or Sell Opportunity • Apr 11
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.0% to €0.46. The fair value is estimated to be €0.58, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 43% over the last year. Earnings per share has grown by 50%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 65% per annum over the same time period. New Risk • Jan 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CN¥24m net loss in 3 years). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (4.9% increase in shares outstanding). Recent Insider Transactions • Jan 17
Key Executive recently bought €89k worth of stock On the 11th of January, Xiaoying Feng bought around 182k shares on-market at roughly €0.49 per share. This transaction amounted to 86% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xiaoying has been a buyer over the last 12 months, purchasing a net total of €171k worth in shares. Reported Earnings • Dec 31
First half 2024 earnings released: CN¥0.072 loss per share (vs CN¥0.36 loss in 1H 2023) First half 2024 results: CN¥0.072 loss per share (improved from CN¥0.36 loss in 1H 2023). Revenue: CN¥356.5m (down 25% from 1H 2023). Net loss: CN¥75.8m (loss narrowed 79% from 1H 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Healthcare Services industry in Europe. New Risk • Dec 03
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CN¥350m Forecast net loss in 3 years: CN¥31m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CN¥31m net loss in 3 years). Shareholders have been diluted in the past year (6.0% increase in shares outstanding). Duyuru • Nov 18
Yidu Tech Inc. to Report Q2, 2024 Results on Nov 29, 2023 Yidu Tech Inc. announced that they will report Q2, 2024 results on Nov 29, 2023 New Risk • Aug 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risk Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Breakeven Date Change • Jul 06
Forecast to breakeven in 2026 The 6 analysts covering Yidu Tech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 50% per year to 2025. The company is expected to make a profit of CN¥53.8m in 2026. Average annual earnings growth of 67% is required to achieve expected profit on schedule. Reported Earnings • Jul 02
Full year 2023 earnings released: CN¥0.63 loss per share (vs CN¥0.80 loss in FY 2022) Full year 2023 results: CN¥0.63 loss per share (improved from CN¥0.80 loss in FY 2022). Revenue: CN¥804.7m (down 35% from FY 2022). Net loss: CN¥628.0m (loss narrowed 18% from FY 2022). Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 6.7% growth forecast for the Healthcare Services industry in Europe. Duyuru • Jun 16
Yidu Tech Inc. to Report Fiscal Year 2023 Results on Jun 30, 2023 Yidu Tech Inc. announced that they will report fiscal year 2023 results on Jun 30, 2023 Breakeven Date Change • Feb 03
No longer forecast to breakeven The 4 analysts covering Yidu Tech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CN¥89.3m in 2025. New consensus forecast suggests the company will make a loss of CN¥64.8m in 2025. Reported Earnings • Dec 30
First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.47 loss in 1H 2022) First half 2023 results: CN¥0.36 loss per share (improved from CN¥0.47 loss in 1H 2022). Revenue: CN¥474.4m (down 5.5% from 1H 2022). Net loss: CN¥353.5m (loss narrowed 20% from 1H 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Healthcare Services industry in Europe. Reported Earnings • Nov 26
First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.47 loss in 1H 2022) First half 2023 results: CN¥0.36 loss per share (improved from CN¥0.47 loss in 1H 2022). Revenue: CN¥474.4m (down 5.5% from 1H 2022). Net loss: CN¥353.5m (loss narrowed 20% from 1H 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Healthcare Services industry in Europe. Board Change • Nov 16
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Linqing Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Jul 30
Full year 2022 earnings released: CN¥0.80 loss per share (vs CN¥7.25 loss in FY 2021) Full year 2022 results: CN¥0.80 loss per share (up from CN¥7.25 loss in FY 2021). Revenue: CN¥1.24b (up 43% from FY 2021). Net loss: CN¥762.3m (loss narrowed 79% from FY 2021). Over the next year, revenue is forecast to grow 42%, compared to a 16% growth forecast for the industry in Germany. Breakeven Date Change • Jun 28
Forecast to breakeven in 2025 The 4 analysts covering Yidu Tech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 24% per year to 2024. The company is expected to make a profit of CN¥167.4m in 2025. Average annual earnings growth of 57% is required to achieve expected profit on schedule. Reported Earnings • Jun 25
Full year 2022 earnings released: CN¥0.80 loss per share (vs CN¥7.25 loss in FY 2021) Full year 2022 results: CN¥0.80 loss per share (up from CN¥7.25 loss in FY 2021). Revenue: CN¥1.24b (up 43% from FY 2021). Net loss: CN¥762.3m (loss narrowed 79% from FY 2021). Over the next year, revenue is forecast to grow 60%, compared to a 22% growth forecast for the industry in Germany. Board Change • Apr 27
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Linqing Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Recent Insider Transactions • Mar 19
Executive Director recently bought €114k worth of stock On the 16th of March, Shi Zhang bought around 129k shares on-market at roughly €0.88 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €156k more in shares than they have sold in the last 12 months. Reported Earnings • Nov 28
First half 2022 earnings: EPS in line with expectations, revenues disappoint First half 2022 results: CN¥0.47 loss per share. Revenue: CN¥501.9m (flat on 1H 2021). Net loss: CN¥440.8m (flat on 1H 2021). Revenue missed analyst estimates by 38%. Over the next year, revenue is forecast to grow 73%, compared to a 81% growth forecast for the industry in Germany. Executive Departure • Oct 03
Non-executive Director Yongmei Gao has left the company On the 26th of September, Yongmei Gao's tenure as Non-executive Director ended after 1.1 years in the role. We don't have any record of a personal shareholding under Yongmei's name. Yongmei is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.17 years, which is considered inexperienced in the Simply Wall St Risk Model. Breakeven Date Change • Jul 09
Forecast breakeven pushed back to 2024 The 4 analysts covering Yidu Tech previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 70% per year to 2023. The company is expected to make a profit of CN¥691.0m in 2024. Average annual earnings growth of 105% is required to achieve expected profit on schedule. 
